Pfizer and its German partner BioNTech are ending a clinical trial they agreed to run in 2025 when receiving approval from U.S. authorities for their updated COVID-19 immunization.
A BioNTech spokesperson confirmed on April 2 that the companies are halting the trial, which was slated to compare healthy vaccine recipients with placebo controls to evaluate the safety and efficacy of the vaccine.
“Notably, this study is not ending as a result of any safety or benefit-risk concerns,” the spokesperson told The Epoch Times in an email. “We intend to stop the study due to slow enrollment and therefore the inability to generate relevant post-marketing data. We will inform the public about any updates in due time.”…